FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Biotech Enterprise Capital Monitor – USA 09/2022”.
The Monitor is a month-to-month revealed overview of enterprise capital traits within the US-Biotech sector.
As of the top of September 2022, we determine the next present VC traits within the US-Biotech sector:
- In 2022, general Biotech funding within the USA has reached USD 23,869m up to now
- The highest 5 offers exceed USD 340m every, largest transaction amounted to USD 3,000m in Altos Labs
- ARCH Enterprise Companions (USA) is main the High 5 Buyers (by deal quantity), adopted by 8VC (USA) and Alexandria Enterprise Investments (USA)
- Oncology dominates as the highest indication
To entry the total report, please click on right here.
By Dr. Mathias Schott, Sebastian Sommer and Johannes Hyperlink